Palvella Therapeutics, Inc. insider trading
Every open-market purchase and sale by Palvella Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Palvella Therapeutics, Inc.’s insiders pay?
From July 8, 2015 to September 4, 2026, 16 insiders reported 15 open-market purchases and 8 sales not made under a pre-set plan in Palvella Therapeutics, Inc. Twelve months after each purchase was reported, the shares were +267.2% against the S&P 500 on average (median +168.1%), over 5 purchases with a full year of prices; 60% beat the index. After sales, the shares moved −59.5% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 17, 2018 into $93,532 by November 2, 2026, +30.3% a year. It held shares 42% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $18,229 (+7.4% a year), and held throughout $31,631 (+14.6%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Jenkins George M | Director | 4 | +609.3% (2) | 100% | 0 | — | April 1, 2026 |
| Geraghty James A | Director | 2 | −45.0% (1) | 0% | 0 | — | May 16, 2018 |
| Isaly Samuel D | 10% owner | 1 | — | — | 1 | −56.9% (1) | January 4, 2018 |
| Kiritsy Christopher P | Director | 1 | −5.5% (1) | 0% | 1 | — | September 4, 2026 |
| Orbimed Capital Gp III LLC | 10% owner | 0 | — | — | 2 | −59.5% (2) | February 15, 2018 |
| Adar1 Capital Management, LLC | 10% owner | 1 | +168.1% (1) | 100% | 0 | — | August 12, 2024 |
| Aquilo Capital Management, LLC | 10% owner | 0 | — | — | 1 | — | July 22, 2020 |
| Bvf Partners Os Ltd. | 10% owner | 0 | — | — | 1 | −59.2% (1) | September 10, 2019 |
| Demuth Tim | Chief Medical Officer | 1 | — | — | 0 | — | May 16, 2022 |
| Heron Elaine J | Director | 1 | — | — | 0 | — | March 2, 2026 |
| Khuong Chau Quang | Director | 1 | — | — | 0 | — | July 8, 2015 |
| Matis Louis | SVP, Chief Development Officer | 1 | — | — | 0 | — | June 15, 2016 |
| Olwill Shane | Chief Development Officer | 0 | — | — | 1 | −61.1% (1) | September 1, 2021 |
| Orbimed Advisors LLC | 10% owner | 0 | — | — | 1 | −61.1% (1) | May 2, 2018 |
| Reine Allan | See Remarks | 1 | — | — | 0 | — | August 17, 2017 |
| Yoder Stephen S. | President and CEO | 1 | — | — | 0 | — | June 15, 2016 |
When several insiders traded Palvella Therapeutics, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Palvella Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged +14.8% against the index. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2026 | 2 buying | −4.0% | −7.2% | not yet |
| August 31, 2017 | 2 buying | +4.5% | +36.8% | −19.0% |